VaramirStart free · no cardSign in
REPL as of Oct 31 · 16:23 ET
REPLNasdaqBiological Products, (No Diagnostic Substances)

Replimune Group, Inc. · Brief

Next report

94 days

Feb 2 · before openest.Q3 FY27
Earnings

Expected move

Inputs

Implied vs realized

8 reportsHistory
1 of 8≥ implied
avg implied
±11.1%
avg realized
±5.8%
Feb 12 '25±11.8%▲+7.32%×0.62
May 22 '25±22.9%▲+3.55%×0.15
Aug 7 '25±8.5%▼−0.36%×0.04
Q2 FY26±9.6%▼−0.93%×0.10
Q3 FY26±7.5%▲+5.81%×0.77
Q1 FY27±13.9%▼−3.70%×0.27
Aug 14 '26±5.0%▼−1.45%×0.29
Q2 FY27±9.9%▲+23.07%×2.32
quarterimplied−25%0+25%realized×
Q2 FY27±9.9%▲+23.07%×2.32
Aug '26±5.0%▼−1.45%×0.29
Q1 FY27±13.9%▼−3.70%×0.27
Q3 FY26±7.5%▲+5.81%×0.77
Q2 FY26±9.6%▼−0.93%×0.10
Aug '25±8.5%▼−0.36%×0.04
2 older reports
May '25±22.9%▲+3.55%×0.15
Feb '25±11.8%▲+7.32%×0.62
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Feb 2 report · est.

—

Linked exposure

REPL report session

No linked exposure.

Latest changes

30 daysAll changes
Oct 27impliedImplied move: ±9.9% into Oct 28 earnings (Oct 27 close).Source
Oct 22impliedImplied move: ±12.6% into Nov 5 earnings (Oct 22 close).Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.